What's Happening?
Advanced Biomed Inc., a biotechnology company, has announced the launch of its A+PerfusC™ system, a perfusion-based 3D cell culture incubator designed to replicate human physiological conditions in vitro. The system integrates automated perfusion with environmental control, supporting up to 12 days of continuous culture, which reduces human error and contamination risks. It promotes spheroid and organoid formation, enhancing cell viability and drug response predictability. The platform is characterized by its ability to support high-throughput drug screening and is expandable to control multiple incubators. The company is advancing mass-production development and aims to commercialize the system following quality control standards establishment.
Why It's Important?
The launch of the A+PerfusC™ system is significant for the biotechnology industry, particularly in precision medicine and drug discovery. By providing a more accurate replication of human tissue complexity, the system enhances drug response modeling and disease research. This innovation could lead to advancements in personalized oncology research, regenerative medicine, and stem cell studies. The global 3D cell culture market is projected to grow significantly, indicating potential economic benefits and increased research capabilities. Stakeholders in the biomedical field stand to gain from improved research tools and methodologies.
What's Next?
Advanced Biomed Inc. plans to scale up the A+PerfusC™ system for high-throughput use and integrate imaging with AI-driven analytics. This development aims to accelerate tumor profiling, refine cell therapy protocols, and advance personalized treatment development. The company is also working on regulatory clearances in China and plans for future global expansion, which could further enhance its market presence and impact.
